Best Peptides for Libido
Sexual desire and arousal are primarily central nervous system functions, not peripheral ones. The most clinically meaningful advance in libido research has been the recognition that effective sexual health interventions need to address brain-level arousal circuitry, not just peripheral vascular or hormonal mechanisms. This guide ranks the best peptides for libido by evidence quality and mechanism clarity, from the only FDA-approved peptide for sexual desire disorder to the hormonal foundations of sexual drive—and what each compound's evidence does and does not establish.
PT-141 is the only peptide in this guide with FDA approval, cleared in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women. It works centrally via melanocortin receptors, distinguishing it mechanistically from PDE5 inhibitors. Kisspeptin restores the hormonal foundation of libido through HPG axis activation and has human fMRI evidence showing direct effects on sexual brain circuits. Melanotan II is a non-selective precursor compound with less favorable regulatory characterization.
Sexual Health · Evidence Map
Best Peptides for Libido
4 compounds ranked · Updated July 2026
The only FDA-approved peptide for sexual desire disorder, with Phase 3 evidence for the specific approved indication
- Dose
- Approved-product dosing is indication-specific and clinician-directed; not a research-use protocol
- Half-life
- ~2.7 hours
A central research model for reproductive-axis physiology with published human fMRI data on sexual brain circuit activation
- Dose
- Research-study protocols vary; not dosing guidance
- Half-life
- Kisspeptin-10: ~30-60 minutes
A historical melanocortin pharmacology research compound; the precursor to FDA-approved PT-141
- Dose
- Research-study protocols vary; not dosing guidance
- Half-life
- ~30 minutes
A research compound for studying dopamine pathway normalization with preclinical data relevant to dopaminergic sexual motivation
- Dose
- Research-study protocols vary; not dosing guidance
- Half-life
- ~4-6 hours
What Libido Peptide Research Actually Shows
- 1PT-141 (Bremelanotide) is the only FDA-approved peptide specifically for sexual dysfunction, approved for the specific indication of HSDD in premenopausal women. Its approval does not cover all sexual dysfunction, all populations, or off-label uses. The contraindications documented in clinical trials (nitrates, antihypertensives) and the pharmacokinetic profile are defined by the FDA label and should be understood within that regulatory context.
- 2PT-141 causes a transient average blood pressure elevation (approximately +6 mmHg systolic, +3 mmHg diastolic) documented in clinical trials. This is a well-characterized pharmacological effect of MC4R activation in the dorsal vagal complex. The FDA label specifically contraindicates concurrent use with nitrate medications and advises caution with antihypertensives. This interaction risk is essential research safety context.
- 3Melanotan-2's sexual side effects were an incidental discovery during University of Arizona tanning research in the early 1990s. The compound was not designed as a sexual function peptide. This origin story explains why the tanning and libido dose ranges studied in early trials differ and why its non-selective pharmacology created both intended (melanogenesis) and unintended (sexual arousal, nausea, flushing) effects.
- 4Kisspeptin's pro-sexual effects in humans were demonstrated in fMRI imaging by Comninos et al. (2017, Imperial College London) showing that kisspeptin administration in healthy male volunteers increased limbic system response to sexual stimuli. This is human neuroimaging evidence for central sexual arousal modulation. These are research observations from a specific study design and do not establish kisspeptin as a treatment for sexual dysfunction.
- 5PT-141's onset in the RECONNECT Phase 3 trials was 45 to 75 minutes with peak effects at 2 to 3 hours. Trial data indicate effects fall within the absorption phase in subjects observed early in the window, consistent with the pharmacokinetic profile documented in the FDA prescribing information for the Vyleesi indication. These are trial-population pharmacokinetic observations, not administration guidance.
Evidence-Ranked Comparison
| Peptide | Evidence | |
|---|---|---|
#1PT-141 (Bremelanotide) | Strong Evidence | Full Profile → |
#2Kisspeptin | Moderate Evidence | Full Profile → |
#3Melanotan II | Preliminary Evidence | Full Profile → |
#4BPC-157 | Preliminary Evidence | Full Profile → |
Detailed Peptide Profiles
PT-141 (Bremelanotide)
Strong EvidenceFDA ApprovedMelanocortinCNS MechanismWomen's HealthThe only FDA-approved peptide for sexual desire disorder, with Phase 3 evidence for the specific approved indication
Bremelanotide (PT-141, brand name Vyleesi) received FDA approval in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. The approval was based on two pivotal Phase 3 trials (RECONNECT studies) demonstrating significant improvements in sexual desire (Female Sexual Function Index) and reductions in distress about low sexual desire compared to placebo. Male use for erectile dysfunction has Phase 3 data but was not pursued to FDA approval. The approved indication is specifically premenopausal women with HSDD; use outside this indication is off-label.
- FDA-approved as Vyleesi for HSDD in premenopausal women
- Phase 3 evidence for approved indication
- Central CNS mechanism distinct from PDE5 inhibitors
- Published pharmacokinetic and safety profile from RECONNECT trials
- Approved only for premenopausal women with HSDD; other uses are off-label
- Nausea in approximately 40 percent of subjects in trials
- Transient blood pressure increase
- Contraindicated with nitrate medications
Kisspeptin
Moderate EvidenceHuman DataHPG AxisfMRI EvidenceCNSA central research model for reproductive-axis physiology with published human fMRI data on sexual brain circuit activation
Comninos and Dhillo's group at Imperial College London published fMRI studies showing that intravenous Kisspeptin-54 administration in men enhanced activation of brain regions associated with sexual processing (including the nucleus accumbens and anterior cingulate cortex) in response to sexual stimuli. A subsequent study showed that Kisspeptin also improved sexual function and mood in hypogonadal men in whom testosterone was normalized by Kisspeptin administration, suggesting both direct CNS and indirect hormonal pathways. These are research findings from specific study populations, not established treatments for sexual dysfunction.
- Dual CNS plus hormonal mechanism with human evidence
- Human fMRI evidence for sexual brain circuit activation (published)
- HPG axis testosterone restoration preserves natural function
- Useful reproductive-axis research model
- Research stage only; no approved formulation for this indication
- IV administration in most published studies
- Sexual dysfunction symptoms require clinical evaluation
- Short half-life requires frequent dosing for sustained effects
Melanotan II
Preliminary EvidenceResearch ChemicalMelanocortinHistorical ContextA historical melanocortin pharmacology research compound; the precursor to FDA-approved PT-141
Melanotan II is a cyclic non-selective agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R. Early Phase 1 and 2 studies documented spontaneous penile erections and sexual arousal in male research subjects, which prompted development of PT-141 as a more selective derivative. Its non-selective MC1R activation produces significant skin pigmentation (tanning) alongside sexual arousal effects. Its superseded status relative to PT-141 reflects the more favorable side effect profile of its derivative; Melanotan II lacks the systematic safety characterization needed for regulatory approval and has more pronounced side effects.
- Early human studies documenting sexual arousal effects
- Non-selective melanocortin pharmacology useful as comparison
- Historical context for PT-141 development
- Non-selective: more side effects than PT-141
- Nausea, facial flushing, and spontaneous erections are documented
- Not approved for any indication
- No systematic safety characterization adequate for regulatory approval
BPC-157
Preliminary EvidenceResearch ChemicalDopaminePreclinicalA research compound for studying dopamine pathway normalization with preclinical data relevant to dopaminergic sexual motivation
BPC-157's relevance to sexual function is through dopaminergic and nitric oxide pathway modulation. BPC-157 has shown normalization of dopamine receptor function and dopaminergic pathways in multiple rodent models of dopaminergic dysfunction. Additionally, BPC-157 upregulates endothelial nitric oxide synthase and promotes nitric oxide production. Rodent studies show improvements in sexual behavior parameters in animals with dopaminergic dysfunction. Human data for this specific application is absent, and the mechanism is several steps removed from the direct CNS arousal effects of PT-141.
- Dopamine pathway normalization data in animal models
- Nitric oxide upregulation with vascular implications
- Well-tolerated in preclinical studies
- Very indirect mechanism for sexual function specifically
- No human data for sexual function indication
- Primarily healing peptide with secondary sexual-relevance hypothesis
How to Choose the Right Peptide
| Your Goal | Best Choice |
|---|---|
| Understanding the evidence for the only FDA-approved sexual desire peptide | PT-141 (Bremelanotide/Vyleesi) prescribing information and clinical literature |
| Studying hormonal and CNS mechanisms of libido in research settings | Kisspeptin literature |
| Understanding melanocortin receptor pharmacology and PT-141 development history | Melanotan II vs PT-141 comparative literature |
| Studying dopaminergic mechanisms in sexual motivation research | BPC-157 dopaminergic mechanism literature |
Research Background
Central vs Peripheral Mechanisms for Sexual Function
Sexual response involves two distinct systems: central (CNS) arousal initiation and peripheral (vascular, hormonal) execution. PDE5 inhibitors (sildenafil, tadalafil) increase cGMP in penile smooth muscle to enhance vasodilation and erection, but only if central arousal is already present and vascular anatomy is intact. PT-141's significance is that it targets the central mechanism directly, activating melanocortin 3 and 4 receptors in the hypothalamic paraventricular nucleus and other limbic structures that initiate the sexual arousal cascade. This explains why PT-141 can show efficacy in situations where PDE5 inhibitors fail: it operates at a different level of the sexual response pathway. This distinction is the scientific basis for PT-141's FDA approval for HSDD, a condition where peripheral mechanisms are intact but central desire is absent.
Melanocortin Receptors and Sexual Arousal Circuits
Five melanocortin receptors (MC1R through MC5R) mediate the diverse effects of melanocortin peptides throughout the body. MC1R controls skin and hair pigmentation; MC2R mediates ACTH effects on the adrenal gland; MC3R and MC4R are the receptors relevant to sexual function. MC4R is highly expressed in the hypothalamic paraventricular nucleus, a key integration center for sexual motivation. PT-141's activation of both MC3R and MC4R addresses both motivational (desire) and physiological arousal components. The most common side effect, nausea, results from MC4R activation in the dorsal vagal complex outside the BBB. PT-141's selectivity compared to Melanotan II reduces MC1R-mediated melanogenesis while maintaining the sexual arousal mechanism.
HSDD: Hypoactive Sexual Desire Disorder and the FDA Approval Context
Hypoactive sexual desire disorder (HSDD) affects approximately 10 percent of premenopausal women and is characterized by persistent low sexual desire causing significant personal distress. PT-141 (Vyleesi) received FDA approval for this specific indication in 2019, providing a second pharmacological option alongside flibanserin (Addyi, approved 2015). The RECONNECT Phase 3 trials demonstrated statistically and clinically significant improvements in satisfying sexual events and sexual desire scores. The approval specifically covers premenopausal women with HSDD; postmenopausal women with HSDD have different hormonal drivers requiring different interventions. Male use remains off-label.
Kisspeptin's Dual Role: HPG Axis and CNS Arousal
Kisspeptin's distinctiveness in libido research is that it appears to simultaneously address both the hormonal foundation of libido (testosterone via HPG axis activation) and CNS arousal circuitry directly. The 2017 fMRI study (Comninos et al., Imperial College London) showed that Kisspeptin administration enhanced activation of the nucleus accumbens (dopamine reward center) in response to sexual stimuli while simultaneously reducing the neural response to aversive sexual content in healthy male volunteers. This is human neuroimaging evidence for central sexual arousal modulation, making it mechanistically distinct from other peptides in this category. These findings are research observations that do not establish kisspeptin as a treatment for sexual dysfunction.
Melanotan II and PT-141: Development History
The development of PT-141 from Melanotan II is an example of pharmacological refinement. Melanotan II was originally developed as a potential sunless tanning agent: it activates MC1R on melanocytes to increase melanin production. During Phase 1 studies at the University of Arizona in the early 1990s, male subjects reported unexpected spontaneous erections, which redirected research interest toward sexual function. Melanotan II's non-selectivity at MC1R, MC3R, MC4R, and MC5R was responsible for both the desired sexual effects and significant side effects. PT-141 was synthesized to reduce MC1R activation while maintaining MC3R/MC4R efficacy, resulting in improved tolerability that enabled FDA approval.
Research & Educational Use Only: All peptides and compounds referenced in this guide are research chemicals documented for scientific education. This content does not constitute medical advice. All compounds should only be used for legitimate laboratory research in accordance with applicable laws. Consult a licensed physician or researcher before any use.
Common Research Protocol Mistakes
Using PT-141 with nitrate medications or combining with antihypertensives
PT-141 causes transient blood pressure elevation through its melanocortin receptor mechanism. Nitrate medications lower blood pressure through nitric oxide mechanisms and are contraindicated with PT-141 per the FDA label. Antihypertensive medications may compound this blood pressure effect. The FDA prescribing information for Bremelanotide specifically addresses these interactions, and they should be understood before any research protocol design.
Treating Melanotan II tanning and libido dose ranges as interchangeable
Melanotan II was developed as a tanning agent, and the doses studied for melanin induction differ from those that documented sexual arousal as an incidental finding in Phase 1 studies. The two applications were studied at different doses for different purposes. Conflating them misunderstands the compound's pharmacological development history and the population-specific nature of the early sexual arousal findings.
Extending PT-141's HSDD indication to all sexual dysfunction contexts
PT-141's FDA approval is specifically for hypoactive sexual desire disorder in premenopausal women. Postmenopausal HSDD, male sexual dysfunction, erectile dysfunction without desire disorder, and other sexual health conditions are not covered by this approval. Extending the indication misrepresents the regulatory evidence base and may expose research subjects to off-label risks without established benefit for the specific context.
Ignoring the pharmacokinetic onset profile documented in the PT-141 approval trials
The RECONNECT Phase 3 trials documented PT-141 onset at 45 to 75 minutes with peak central MC4R occupancy at 2 to 3 hours. Research protocols that do not account for this onset window may observe effects in the absorption phase before peak receptor occupancy. The pharmacokinetic profile is documented in the FDA prescribing information for the Vyleesi indication and should inform research protocol design.
Frequently Asked Questions
What peptide is FDA-approved for sexual desire?
PT-141 (Bremelanotide, brand name Vyleesi) is the only FDA-approved peptide for sexual desire disorder, cleared in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works centrally via MC3R and MC4R melanocortin receptors in the hypothalamus and limbic system. This approval is for a specific indication in a specific population; use outside this approved indication is off-label.
Does PT-141 work for men?
Phase 3 clinical trials demonstrated PT-141 improves erectile function and sexual desire in men with erectile dysfunction, including cases where PDE5 inhibitors had failed. The mechanism (MC3R/MC4R activation in hypothalamic arousal circuits) is not sex-specific. However, PT-141 was submitted to the FDA with a female HSDD indication (Vyleesi), and the male ED indication was not pursued commercially. Male use constitutes off-label use outside the approved indication.
What is the difference between PT-141 and Melanotan II?
Both activate melanocortin receptors, but with important differences. Melanotan II is a cyclic non-selective agonist at MC1R, MC3R, MC4R, and MC5R, producing strong skin tanning (MC1R) alongside sexual arousal (MC3R/MC4R). PT-141 is a linear analog designed to reduce MC1R activation, preserving sexual arousal efficacy while greatly reducing melanogenesis. PT-141 achieved FDA approval based on its improved safety and tolerability profile; Melanotan II lacks systematic safety characterization needed for regulatory approval and has more pronounced side effects.
How long does PT-141 take to produce effects in the approved indication?
In the FDA approval trials (RECONNECT studies), bremelanotide reached peak plasma concentration within approximately 1 hour and sexual arousal effects were observed within 45–90 minutes in the studied population. Trial-observed effects lasted approximately 6–12 hours. These are pharmacokinetic findings from the specific clinical trial populations used for the premenopausal HSDD indication; they describe trial outcomes, not a self-administration protocol.
Research Peptide Vendor List
These are the research peptide vendors we track. Each supplier is scored on published certificate of analysis practice, independent testing, review record, and operating history. All compounds are sold for laboratory research use only.
- Kylo Peptides VerifiedBatch-level third-party COA3.9 from 12 reviews
- Biolongevity Labs VerifiedBatch-level third-party COA4.0 from 5 reviews
- MyBioSource VerifiedBatch-level third-party COA3.4 from 5 reviews
- Biotech Peptides VerifiedBatch-level third-party COA2.6 from 17 reviews
- AminoClub VerifiedBatch-level third-party COA3.0 from 3 reviews
- Core Peptides VerifiedBatch-level third-party COA3.0 from 3 reviews
Related Research Guides
Want to compare peptides interactively?
Use our interactive comparison tool or stack builder to design your research protocol.